Literature DB >> 19911699

Dexamethasone downregulates BCRP mRNA and protein expression in breast cancer cell lines.

Fatemeh Elahian1, Fatemeh Kalalinia, Javad Behravan.   

Abstract

It is hypothesized that anti-inflammatory drugs regulate breast cancer resistance protein (BCRP) expression. Hence, we examined the effects of indomethacin and dexamethasone on BCRP expression in MCF cells. For evaluation of BCRP mRNA expression, relative quantitative PCR and comparative C1 method was exploited. BCRP protein expression was measured flow cytometrically with the monoclonal antibody (mAb) BXP-21. Dexamethasone showed a dose-independent and a time-dependent effect on decreasing the mRNA level of BCRP gene in comparison with control in MCF-7 and MCF-7/MX breast cancer cell lines, whereas no changes were noted in the presence of indomethacin. The level of BCRP protein, expressed as a ratio of the corresponding control, was decreased in dexamethasone-treated MCF-7/MX cells. These results could be of great importance when combination therapy protocols with cytotoxic agents and dexamethasone regimens are considered in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19911699     DOI: 10.3727/096504009789745674

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  11 in total

1.  The anticancer agent prodigiosin is not a multidrug resistance protein substrate.

Authors:  Fatemeh Elahian; Bahareh Moghimi; Farideh Dinmohammadi; Mahsa Ghamghami; Mehrdad Hamidi; Seyed Abbas Mirzaei
Journal:  DNA Cell Biol       Date:  2013-02-01       Impact factor: 3.311

Review 2.  ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.

Authors:  Maryam Hosseini Hasanabady; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

Review 3.  Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness.

Authors:  Neda Gholamian Dehkordi; Seyed Abbas Mirzaei; Fatemeh Elahian
Journal:  Inflammopharmacology       Date:  2020-10-17       Impact factor: 4.473

4.  Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.

Authors:  Fatemeh Mosaffa; Fatemeh Kalalinia; Herman Lage; Jalil Tavakol Afshari; Javad Behravan
Journal:  Mol Cell Biochem       Date:  2011-12-23       Impact factor: 3.396

5.  Breast cancer-resistance protein (BCRP1) in the fetal mouse brain: development and glucocorticoid regulation.

Authors:  Sophie Petropoulos; William Gibb; Stephen G Matthews
Journal:  Biol Reprod       Date:  2010-12-15       Impact factor: 4.285

6.  Expression of Drug Pump Protein MRP2 in Lipopolysaccharide-Treated Rats and its Impact on the Disposition of Acetaminophen.

Authors:  Mitra Hassany; Mohammad Hassanzadeh Khayat; Javaad Behravan; Jamaal Kasaeeian
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

7.  Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines.

Authors:  Fatemeh Kalalinia; Fatemeh Elahian; Fatemeh Mosaffa; Javad Behravan
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

8.  shRNA-mediated downregulation of α-N-Acetylgalactosaminidase inhibits migration and invasion of cancer cell lines.

Authors:  Ehsan Saburi; Jalil Tavakolafshari; Yousef Mortazavi; Alireza Biglari; Seyed Abbas Mirzaei; Samad Nadri
Journal:  Iran J Basic Med Sci       Date:  2017-09       Impact factor: 2.699

9.  Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice.

Authors:  Atefeh Razazan; Jessica Nicastro; Roderick Slavcev; Nastaran Barati; Atefeh Arab; Fatemeh Mosaffa; Mahmoud Reza Jaafari; Javad Behravan
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

10.  Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells.

Authors:  Seyed Abbas Mirzaei; Somayeh Reiisi; Parmida Ghiasi Tabari; Abolfazl Shekari; Fatemeh Aliakbari; Elaheh Azadfallah; Fatemeh Elahian
Journal:  Sci Rep       Date:  2018-02-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.